Evolution of the HIV-1 nefgene in HLA-B*57 Positive Elite Suppressors
© Salgado et al; licensee BioMed Central Ltd. 2010
Received: 26 September 2010
Accepted: 8 November 2010
Published: 8 November 2010
Elite controllers or suppressors (ES) are HIV-1 infected patients who maintain viral loads of < 50 copies/ml without antiretroviral therapy. CD8+ T cells are thought to play a key role in the control of viral replication and exert selective pressure on gag and nef in HLA-B*57 positive ES. We previously showed evolution in the gag gene of ES which surprisingly was mostly due to synonymous mutations rather than non-synonymous mutation in targeted CTL epitopes. This finding could be the result of structural constraints on Gag, and we therefore examined the less conserved nef gene. We found slow evolution of nef in plasma virus in some ES. This evolution is mostly due to synonymous mutations and occurs at a rate similar to that seen in the gag gene in the same patients. The results provide further evidence of ongoing viral replication in ES and suggest that the nef and gag genes in these patients respond similarly to selective pressure from the host.
The mechanisms responsible for the control of the HIV-1 replication in elite suppressors are not fully understood [1–3]. Replication competent virus has been isolated from some ES [4–6] and genotypic , phenotypic , and epidemiologic  analyses have suggested that these isolates are generally fully pathogenic. Thus it appears that in many cases, host factors rather than infection with defective virus are responsible for the elite control of viral replication. The HLA-B*57 allele is overrepresented in ES [8–14] which suggests an important role of CD8+ T cells. These cells have been shown to exert selective pressure on HLA-B*57 restricted epitopes in ES [15–17] and LTNPs , and we have previously documented evidence of evolution in the gag gene in plasma virus of HLA-B*57 positive ES over a 5 year period . However, some studies have suggested that Gag is preferentially targeted by CD8+ T cells in patients who control viremia [12, 20] and it is therefore possible that viral evolution in ES is limited to this gene. To test this hypothesis, we analyzed proviral and plasma nef sequences in ES over a 6 year period and compared the rate of evolution in these two compartments to the rate of evolution of observed for the gag gene.
Four previously described HLA-B*57 ES patients were studied [16, 21]. Viral RNA was isolated from plasma, and genomic DNA was purified from resting CD4+ T cells as described previously . To limit PCR resampling, nef genes were amplified from provirus in genomic DNA and from plasma-derived RNA by limiting dilution "digital" nested PCR using previously described primers and conditions . PCR products were directly sequenced using an ABI PRISM 3700 DNA analyzer (Applied Biosystems). Chromatograms were manually examined for the presence of double peaks indicative of two templates per sequencing reaction. Such sequences were discarded. Sequences were assembled using CodonCode Aligner, version 1.3.1, aligned using ClustalX, and the alignments were manually adjusted in Bioedit. Sequences were translated in Bioedit, and the mean number of amino acid differences between all provirus nef and all plasma virus nef sequences from each patient was calculated.
Phylogenetic analysis and statistics
All independent clonal sequences obtained were included in the phylogenetic analysis, with the exception of sequences showing APOBEC3G/F-mediated hypermutation, which were removed. Sequences [GenBank: FJ430356 to FJ430471 and HQ448774 to HQ448852] subsequently were handled as previously described . Classical, maximum-likelihood, and Bayesian phylogenetic reconstruction for each patient was performed as previously described . Non-synonymous and synonymous p-distance calculations and the number of differences were based on the Nei-Gojobori method  and were calculated by comparing grouped sequences from the early time points in each patient to sequences from the later time points using MEGA 4.0 software .
We performed a longitudinal analysis of viral sequences in 4 ES HLA-B*57+ patients in order to determine whether viral evolution occurred in nef. A median of 12 independent nef clones (range 3 to 17) were amplified from plasma virus of each of the four ES. In three patients, we also amplified a median of 9 nef sequences from proviral DNA in resting CD4+ T cells (range 6 to 16). These new sequences were compared to sequences obtained from the patients 5 to 6 years earlier.
There is substantial evidence that HIV-specific CD8+ T cells that are ES are functionally superior to those found in patients with progressive disease [13, 24–28]. Some studies suggest that Gag is preferentially targeted in patients who control HIV-1 viremia [12, 20] and others have shown that Gag-specific CD8+ T cells are better at inhibiting viral replication than T cells that target Nef . Gag has structural constraints that limit the rate of virologic escape. Also, mutations in some Gag HLA-B*57-restricted epitopes occur at a substantial fitness cost [29, 30], leading to reversion to wild type sequence when mutants are transmitted to HLA-B*57 negative individuals [31, 32]. In contrast, Nef is less constrained and there is not as much evidence for diminished fitness of escape variants. In fact, in one study, mutations in the Nef KF9 epitope did not revert to wild type following transmission to HLA-B*57 negative patients .
We have previously shown that CD8+ T cells exert selective pressure on both Gag  and Nef  in plasma virus. We also recently documented evolution in the gag gene in plasma virus in ES . This evolution was mostly seen in regions outside of epitopes and was due to synonymous mutations. We hypothesized that the lack of non-synonymous mutations was a result of the structural constraints on Gag. One would thus expect to see a higher rate of non-synonymous mutations in Nef. However, in all four patients, we saw very few non-synonymous mutations and a comparable frequency of synonymous mutations in both genes. This analysis is technically challenging because it involves the amplification of multiple clonal sequences from plasma and resting CD4+ T cells of patients who often maintain viral loads of < 1 copy/ml [13, 34–36]. The results suggest that in both Gag and Nef, after early virologic escape occurs, there is little continuing evolution in epitopes as a balance between immune evasion and viral fitness is achieved. However, non-synonymous mutations accumulate in both genes in plasma virus as a result of low level ongoing replication. This finding may have implications for the design of HIV-1 vaccines.
Acknowledgements and Funding
This work was supported by NIH Grant R01 AI080328 (JNB) and the Howard Hughes Medical Institute (RFS)
- Baker BM, Block BL, Rothchild AC, Walker BD: Elite control of HIV infection: implications for vaccine design. Expert Opin Biol Ther. 2009, 9 (1): 55-69. 10.1517/14712590802571928.PubMed CentralView ArticlePubMedGoogle Scholar
- Blankson JN: Effector mechanisms in HIV-1 infected elite controllers: highly active immune responses?. Antiviral Res. 2010, 85 (1): 295-302. 10.1016/j.antiviral.2009.08.007.PubMed CentralView ArticlePubMedGoogle Scholar
- Migueles SA, Connors M: Long-term nonprogressive disease among untreated HIV-infected individuals: clinical implications of understanding immune control of HIV. JAMA. 2010, 304 (2): 194-201. 10.1001/jama.2010.925.View ArticlePubMedGoogle Scholar
- Blankson JN, Bailey JR, Thayil S, Yang HC, Lassen K, Lai J, Gandhi SK, Siliciano JD, Williams TM, Siliciano RF: Isolation and characterization of replication-competent human immunodeficiency virus type 1 from a subset of elite suppressors. J Virol. 2007, 81 (5): 2508-2518. 10.1128/JVI.02165-06.PubMed CentralView ArticlePubMedGoogle Scholar
- Lamine A, Caumont-Sarcos A, Chaix ML, Saez-Cirion A, Rouzioux C, Delfraissy JF, Pancino G, Lambotte O: Replication-competent HIV strains infect HIV controllers despite undetectable viremia (ANRS EP36 study). AIDS. 2007, 21 (8): 1043-1045. 10.1097/QAD.0b013e3280d5a7ac.View ArticlePubMedGoogle Scholar
- Julg B, Pereyra F, Buzon MJ, Piechocka-Trocha A, Clark MJ, Baker BM, Lian J, Miura T, Martinez-Picado J, Addo MM, Walker BD: Infrequent recovery of HIV from but robust exogenous infection of activated CD4(+) T cells in HIV elite controllers. Clin Infect Dis. 2010, 51 (2): 233-238. 10.1086/653677.PubMed CentralView ArticlePubMedGoogle Scholar
- Bailey JR, O'Connell K, Yang HC, Han Y, Xu J, Jilek B, Williams TM, Ray SC, Siliciano RF, Blankson JN: Transmission of human immunodeficiency virus type 1 from a patient who developed AIDS to an elite suppressor. J Virol. 2008, 82 (15): 7395-7410. 10.1128/JVI.00800-08.PubMed CentralView ArticlePubMedGoogle Scholar
- Migueles SA, Sabbaghian MS, Shupert WL, Bettinotti MP, Marincola FM, Martino L, Hallahan CW, Selig SM, Schwartz D, Sullivan J, Connors M: HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. Proc Natl Acad Sci USA. 2000, 97 (6): 2709-2714. 10.1073/pnas.050567397.PubMed CentralView ArticlePubMedGoogle Scholar
- Lambotte O, Boufassa F, Madec Y, Nguyen A, Goujard C, Meyer L, Rouzioux C, Venet A, Delfraissy JF, SEROCO-HEMOCO Study Group: HIV controllers: a homogeneous group of HIV-1-infected patients with spontaneous control of viral replication. Clin Infect Dis. 2005, 41 (7): 1053-1056. 10.1086/433188.View ArticlePubMedGoogle Scholar
- Han Y, Lai J, Barditch-Crovo P, Gallant JE, Williams TM, Siliciano RF, Blankson JN: The role of protective HCP5 and HLA-C associated polymorphisms in the control of HIV-1 replication in a subset of elite suppressors. AIDS. 2008, 22 (4): 541-544. 10.1097/QAD.0b013e3282f470e4.View ArticlePubMedGoogle Scholar
- Emu B, Sinclair E, Hatano H, Ferre A, Shacklett B, Martin JN, McCune JM, Deeks SG: HLA Class I-Restricted T Cell Responses May Contribute to the Control of HIV Infection, but Such Responses are Not Always Necessary for Long-term Virus Control. J Virol. 2008Google Scholar
- Pereyra F, Addo MM, Kaufmann DE, Liu Y, Miura T, Rathod A, Baker B, Trocha A, Rosenberg R, Mackey E, Ueda P, Lu Z, Cohen D, Wrin T, Petropoulos CJ, Rosenberg ES, Walker BD: Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J Infect Dis. 2008, 197 (4): 563-571. 10.1086/526786.View ArticlePubMedGoogle Scholar
- Migueles SA, Osborne CM, Royce C, Compton AA, Joshi RP, Weeks KA, Rood JE, Berkley AM, Sacha JB, Cogliano-Shutta NA, Lloyd M, Roby G, Kwan R, McLaughlin M, Stallings S, Rehm C, O'Shea MA, Mican J, Packard BZ, Komoriya A, Palmer S, Wiegand AP, Maldarelli F, Coffin JM, Mellors JW, Hallahan CW, Follman DA, Connors M: Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control. Immunity. 2008, 29 (6): 1009-1021. 10.1016/j.immuni.2008.10.010.PubMed CentralView ArticlePubMedGoogle Scholar
- Sajadi MM, Constantine NT, Mann DL, Charurat M, Dadzan E, Kadlecik P, Redfield RR: Epidemiologic characteristics and natural history of HIV-1 natural viral suppressors. J Acquir Immune Defic Syndr. 2009, 50 (4): 403-408. 10.1097/QAI.0b013e3181945f1e.PubMed CentralView ArticlePubMedGoogle Scholar
- Migueles SA, Laborico AC, Imamichi H, Shupert WL, Royce C, McLaughlin M, Ehler L, Metcalf J, Liu S, Hallahan CW, Connors M: The differential ability of HLA B*5701+ long-term nonprogressors and progressors to restrict human immunodeficiency virus replication is not caused by loss of recognition of autologous viral gag sequences. J Virol. 2003, 77 (12): 6889-6898. 10.1128/JVI.77.12.6889-6898.2003.PubMed CentralView ArticlePubMedGoogle Scholar
- Bailey JR, Williams TM, Siliciano RF, Blankson JN: Maintenance of viral suppression in HIV-1-infected HLA-B*57+ elite suppressors despite CTL escape mutations. J Exp Med. 2006, 203 (5): 1357-1369. 10.1084/jem.20052319.PubMed CentralView ArticlePubMedGoogle Scholar
- Miura T, Brockman MA, Schneidewind A, Lobritz M, Pereyra F, Rathod A, Block BL, Brumme ZL, Brumme CJ, Baker B, Rothchild AC, Li B, Trocha A, Cutrell E, Frahm N, Brander C, Toth I, Arts EJ, Allen TM, Walker BD: HLA-B57/B*5801 human immunodeficiency virus type 1 elite controllers select for rare gag variants associated with reduced viral replication capacity and strong cytotoxic T-lymphotye recognition. J Virol. 2009, 83 (6): 2743-2755. 10.1128/JVI.02265-08.PubMed CentralView ArticlePubMedGoogle Scholar
- Navis M, Schellens I, van Baarle D, Borghans J, van Swieten P, Miedema F, Kootstra N, Schuitemaker H: Viral replication capacity as a correlate of HLA B57/B5801-associated nonprogressive HIV-1 infection. J Immunol. 2007, 179 (5): 3133-3143.View ArticlePubMedGoogle Scholar
- O'Connell KA, Brennan TP, Bailey JR, Ray SC, Siliciano RF, Blankson JN: Control of HIV-1 in elite suppressors despite ongoing replication and evolution in plasma virus. J Virol. 2010, 84 (14): 7018-7028. 10.1128/JVI.00548-10.PubMed CentralView ArticlePubMedGoogle Scholar
- Kiepiela P, Ngumbela K, Thobakgale C, Ramduth D, Honeyborne I, Moodley E, Reddy S, de Pierres C, Mncube Z, Mkhwanazi N, Bishop K, van der Stok M, Nair K, Khan N, Crawford H, Payne R, Leslie A, Prado J, Prendergast A, Frater J, McCarthy N, Brander C, Learn GH, Nickle D, Rousseau C, Coovadia H, Mullins JI, Heckerman D, Walker BD, Goulder P: CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med. 2007, 13 (1): 46-53. 10.1038/nm1520.View ArticlePubMedGoogle Scholar
- Bailey JR, Brennan TP, O'Connell KA, Siliciano RF, Blankson JN: Evidence of CD8+ T-cell-mediated selective pressure on human immunodeficiency virus type 1 nef in HLA-B*57+ elite suppressors. J Virol. 2009, 83 (1): 88-97. 10.1128/JVI.01958-08.PubMed CentralView ArticlePubMedGoogle Scholar
- Nei M, Gojobori T: Simple methods for estimating the numbers of synonymous and nonsynonymous nucleotide substitutions. Mol Biol Evol. 1986, 3 (5): 418-426.PubMedGoogle Scholar
- Tamura K, Dudley J, Nei M, Kumar S: MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol. 2007, 24 (8): 1596-1599. 10.1093/molbev/msm092.View ArticlePubMedGoogle Scholar
- Migueles SA, Laborico AC, Shupert WL, Sabbaghian MS, Rabin R, Hallahan CW, Van Baarle D, Kostense S, Miedema F, McLaughlin M, Ehler L, Metcalf J, Liu S, Connors M: HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat Immunol. 2002, 3 (11): 1061-1068. 10.1038/ni845.View ArticlePubMedGoogle Scholar
- Betts MR, Nason MC, West SM, De Rosa SC, Migueles SA, Abraham J, Lederman MM, Benito JM, Goepfert PA, Connors M, Roederer M, Koup RA: HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood. 2006, 107 (12): 4781-4789. 10.1182/blood-2005-12-4818.PubMed CentralView ArticlePubMedGoogle Scholar
- Saez-Cirion A, Lacabaratz C, Lambotte O, Versmisse P, Urrutia A, Boufassa F, Barre-Sinoussi F, Delfraissy JF, Sinet M, Pancino G, Venet A, Agence Nationale de Recherches sur le Sida EP36 HIV Controllers Study Group: HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proc Natl Acad Sci USA. 2007, 104 (16): 6776-6781. 10.1073/pnas.0611244104.PubMed CentralView ArticlePubMedGoogle Scholar
- Saez-Cirion A, Sinet M, Shin SY, Urrutia A, Versmisse P, Lacabaratz C, Boufassa F, Avettand-Fenoel V, Rouzioux C, Delfraissy JF, Barre-Sinoussi F, Lambotte O, Venet A, Pancino G, ANRS EP36 HIV Controllers Study Group: Heterogeneity in HIV suppression by CD8 T cells from HIV controllers: association with Gag-specific CD8 T cell responses. J Immunol. 2009, 182 (12): 7828-7837. 10.4049/jimmunol.0803928.View ArticlePubMedGoogle Scholar
- Hersperger AR, Pereyra F, Nason M, Demers K, Sheth P, Shin LY, Kovacs CM, Rodriguez B, Sieg SF, Teixeira-Johnson L, Gudonis D, Goepfert PA, Lederman MM, Frank I, Makedonas G, Kaul R, Walker BD, Betts MR: Perforin expression directly ex vivo by HIV-specific CD8 T-cells is a correlate of HIV elite control. PLoS Pathog. 2010, 6 (5): e1000917-10.1371/journal.ppat.1000917.PubMed CentralView ArticlePubMedGoogle Scholar
- Martinez-Picado J, Prado JG, Fry EE, Pfafferott K, Leslie A, Chetty S, Thobakgale C, Honeyborne I, Crawford H, Matthews P, Pillay T, Rousseau C, Mullins JI, Brander C, Walker BD, Stuart DI, Kiepiela P, Goulder P: Fitness cost of escape mutations in p24 Gag in association with control of human immunodeficiency virus type 1. J Virol. 2006, 80 (7): 3617-3623. 10.1128/JVI.80.7.3617-3623.2006.PubMed CentralView ArticlePubMedGoogle Scholar
- Brockman MA, Schneidewind A, Lahaie M, Schmidt A, Miura T, Desouza I, Ryvkin F, Derdeyn CA, Allen S, Hunter E, Mulenga J, Goepfert PA, Walker BD, Allen TM: Escape and compensation from early HLA-B57-mediated cytotoxic T-lymphocyte pressure on human immunodeficiency virus type 1 Gag alter capsid interactions with cyclophilin A. J Virol. 2007, 81 (22): 12608-12618. 10.1128/JVI.01369-07.PubMed CentralView ArticlePubMedGoogle Scholar
- Leslie AJ, Pfafferott KJ, Chetty P, Draenert R, Addo MM, Feeney M, Tang Y, Holmes EC, Allen T, Prado JG, Altfeld M, Brander C, Dixon C, Ramduth D, Jeena P, Thomas SA, St John A, Roach TA, Kupfer B, Luzzi G, Edwards A, Taylor G, Lyall H, Tudor-Williams G, Novelli V, Martinez-Picado J, Kiepiela P, Walker BD, Goulder PJ: HIV evolution: CTL escape mutation and reversion after transmission. Nat Med. 2004, 10 (3): 282-289. 10.1038/nm992.View ArticlePubMedGoogle Scholar
- Crawford H, Prado JG, Leslie A, Hue S, Honeyborne I, Reddy S, van der Stok M, Mncube Z, Brander C, Rousseau C, Mullins JI, Kaslow R, Goepfert P, Allen S, Hunter E, Mulenga J, Kiepiela P, Walker BD, Goulder PJ: Compensatory mutation partially restores fitness and delays reversion of escape mutation within the immunodominant HLA-B*5703-restricted Gag epitope in chronic human immunodeficiency virus type 1 infection. J Virol. 2007, 81 (15): 8346-8351. 10.1128/JVI.00465-07.PubMed CentralView ArticlePubMedGoogle Scholar
- Leslie A, Kavanagh D, Honeyborne I, Pfafferott K, Edwards C, Pillay T, Hilton L, Thobakgale C, Ramduth D, Draenert R, Le Gall S, Luzzi G, Edwards A, Brander C, Sewell AK, Moore S, Mullins J, Moore C, Mallal S, Bhardwaj N, Yusim K, Phillips R, Klenerman P, Korber B, Kiepiela P, Walker B, Goulder P: Transmission and accumulation of CTL escape variants drive negative associations between HIV polymorphisms and HLA. J Exp Med. 2005, 201 (6): 891-902. 10.1084/jem.20041455.PubMed CentralView ArticlePubMedGoogle Scholar
- Dinoso JB, Kim SY, Siliciano RF, Blankson JN: A comparison of viral loads between HIV-1-infected elite suppressors and individuals who receive suppressive highly active antiretroviral therapy. Clin Infect Dis. 2008, 47 (1): 102-104. 10.1086/588791.PubMed CentralView ArticlePubMedGoogle Scholar
- Hatano H, Delwart EL, Norris PJ, Lee TH, Dunn-Williams J, Hunt PW, Hoh R, Stramer SL, Linnen JM, McCune JM, Martin JN, Busch MP, Deeks SG: Evidence for persistent low-level viremia in individuals who control human immunodeficiency virus in the absence of antiretroviral therapy. J Virol. 2009, 83 (1): 329-335. 10.1128/JVI.01763-08.PubMed CentralView ArticlePubMedGoogle Scholar
- Pereyra F, Palmer S, Miura T, Block BL, Wiegand A, Rothchild AC, Baker B, Rosenberg R, Cutrell E, Seaman MS, Coffin JM, Walker BD: Persistent low-level viremia in HIV-1 elite controllers and relationship to immunologic parameters. J Infect Dis. 2009, 200 (6): 984-990. 10.1086/605446.PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.